GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Notes Receivable

ValiRx (LSE:VAL) Notes Receivable : £0.00 Mil (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Notes Receivable?

ValiRx's Notes Receivable for the quarter that ended in Dec. 2024 was £0.00 Mil.


ValiRx Notes Receivable Historical Data

The historical data trend for ValiRx's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Notes Receivable Chart

ValiRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ValiRx Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ValiRx Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


ValiRx Notes Receivable Related Terms

Thank you for viewing the detailed overview of ValiRx's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx Business Description

Traded in Other Exchanges
N/A
Address
D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.